AI-based drug discovery company Recursion raises $239M Series D and partners with pharma giant Bayer to develop new treatments for fibrotic diseases
Leah Rosenbaum / Forbes :
Context & Ripple Effects
Recursion has been scaling on a steady cadence: after its $121M raise at a $646M valuation in 2019, it added $50M from Nvidia to train its models on its own 23,000TB+ datasets. The new $239M Series D plus a Bayer partnership marks the shift from raising capital to converting that compute-heavy platform into big-pharma revenue.
The deal lands in a field where validation increasingly comes from pharma alliances rather than pure venture money: Formation Bio built its model on co-developing drugs with biotech and pharma companies, while DeepMind spinoff Isomorphic Labs pulled in a $600M round to chase cancer and immune-disorder treatments.
First-order effects
- Bayer gains a route into fibrotic-disease programs built on Recursion's AI models, and Recursion converts its dataset-and-compute investment into its first major pharma development partnership.
- Recursion's war chest roughly triples from its 2019 round, extending runway for its own pipeline alongside the Bayer work.
Second-order effects
- Rival pharma companies now face the same choice Bayer made — partner with an AI discovery platform or watch competitors get first crack at its pipelines — pressuring peers of Bayer toward similar deals.
- Competing platforms like Formation Bio and Isomorphic Labs must match the big-pharma-partnership proof point to justify their own large raises.
Third-order effects
- If the pattern holds, AI drug discovery consolidates into a two-tier structure: capital-intensive platform companies whose valuations rest on pharma alliances, and big pharma acting as distributor and validator rather than primary discoverer — with the sector's funding arc from BenevolentAI's $2.1B valuation through Isomorphic's $600M suggesting the checks keep growing.
The trend: AI drug discovery is moving from venture-funded standalone labs to big-pharma-validated platforms, with partnership deals like Bayer's becoming the sector's key credibility signal.